OTCMKTS:ATBPD Antibe Therapeutics - ATBPD Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Antibe Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $0.44 -0.02 (-4.35%) (As of 03/24/2023 12:00 AM ET) Add Compare Share Share Today's Range$0.44▼$0.4450-Day Range$0.36▼$0.5352-Week Range$2.64▼$3.50Volume12,000 shsAverage Volume29,710 shsMarket Capitalization$170.05 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileChartCompetitorsShort Interest About Antibe Therapeutics (OTCMKTS:ATBPD) StockAntibe Therapeutics Inc., a pharmaceutical development company, originates, develops, and out-licenses patent novel therapeutics and medical devices in the areas of pain, inflammation and regenerative medicine in Canada, Europe, the United States, and internationally. Its drugs are designed to prevent the gastrointestinal damage and bleeding caused by non-steroidal anti-inflammatory drugs. The company's lead compound is ATB-346, a hydrogen sulfide-releasing derivative of naproxen for treating rheumatoid arthritis, ankylosing spondylitis, and general pain reduction that has completed Phase 2B gastrointestinal safety study. Its products also comprise ATB-352, which is in preclinical stage for the treatment of gout, dental pain, post-surgical pain, etc.; and ATB-340 that is in preclinical development stage for the treatment of stroke and cancer. In addition, it offers bone graft substitutes, barrier membranes, and other products for the dental and orthopedic markets under the C-Graft Putty, C-Blast Putty, Eclipse, NeoGuarde, Neomem, Neomem FlexPlus, PentOS OI, and Raptos trademarks. The company was incorporated in 2009 and is headquartered in Toronto, Canada.Read More Receive ATBPD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Antibe Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address ATBPD Stock News HeadlinesNo headlines for this company have been tracked by MarketBeat.com View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive ATBPD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Antibe Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Industry, Sector and Symbol Stock ExchangeOTCMKTS Industry Pharmaceutical Preparations Sub-IndustryN/A SectorMedical Current SymbolOTCMKTS:ATBPD CUSIPN/A CIKN/A Webwww.antibethera.com Phone416 922 3460FaxN/AEmployees47Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($0.60) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-14,540,000.00 Net Margins-273.96% Pretax MarginN/A Return on Equity-150.49% Return on Assets-98.51% Debt Debt-to-Equity RatioN/A Current Ratio5.97 Quick Ratio5.42 Sales & Book Value Annual Sales$7.51 million Price / Sales22.64 Cash FlowN/A Price / Cash FlowN/A Book Value$0.10 per share Price / Book4.39Miscellaneous Outstanding Shares387,000,000Free FloatN/AMarket Cap$170.05 million OptionableNot Optionable Beta0.57 Key ExecutivesMr. Daniel Marcel Legault (Age 62)Pres, CEO, Sec. & Director Dr. John Lawrence Wallace M.B.A. (Age 63)M.Sc., MSc, Ph.D., MBA, Founder, Chief Scientific Officer & Director Mr. Alain Wilson M.B.A.MBA, Chief Financial OfficerDr. David James Vaughan (Age 70)Chief Devel. Officer Mr. Scott Curtis C.F.A.M.Eng, CFA, Exec. VPMs. Christina Cameron B.B.A.VP of Investor RelationsMr. Philip SternVP of CommunicationsDr. Rami Batal M.B.A.Ph.D., Chief Commercial OfficerMs. Ella Korets Smith M.B.A.M.Sc., Head of Regional Bus. Devel.Dr. Joseph Stauffer (Age 54)Chief Medical Officer More ExecutivesKey CompetitorsLianBioNASDAQ:LIANAC ImmuneNASDAQ:ACIUAadi BioscienceNASDAQ:AADIRallybioNASDAQ:RLYBNuvectis PharmaNASDAQ:NVCTView All Competitors ATBPD Stock - Frequently Asked Questions How have ATBPD shares performed in 2023? Antibe Therapeutics' stock was trading at $0.3230 at the beginning of 2023. Since then, ATBPD shares have increased by 36.0% and is now trading at $0.4394. View the best growth stocks for 2023 here. What is Antibe Therapeutics' stock symbol? Antibe Therapeutics trades on the OTCMKTS under the ticker symbol "ATBPD." How do I buy shares of Antibe Therapeutics? Shares of ATBPD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Antibe Therapeutics' stock price today? One share of ATBPD stock can currently be purchased for approximately $0.44. How much money does Antibe Therapeutics make? Antibe Therapeutics (OTCMKTS:ATBPD) has a market capitalization of $170.05 million and generates $7.51 million in revenue each year. The company earns $-14,540,000.00 in net income (profit) each year or ($0.60) on an earnings per share basis. How can I contact Antibe Therapeutics? Antibe Therapeutics' mailing address is 15 PRINCE ARTHUR AVENUE, TORONTO A6, M5R 1B2. The official website for the company is www.antibethera.com. The company can be reached via phone at 416 922 3460 or via email at christina@antibethera.com. This page (OTCMKTS:ATBPD) was last updated on 3/26/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.